PATENT CLAIM ANALYSIS

Application Number: 15934334
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["424", "133100"]

Abstract:
Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.

Claim (Index 103):
The synergistic agonist combination of  claim 100  wherein the CD27 agonist is an agonistic CD27 antibody.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 90.0
- Lexical Diversity: 1.64835
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13905436', '12446322', '14974793', '11743978', '13165154']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.833825658586538
- 35 USC 102 Novelty (BERT): 0.6345684719010237
- Combined Prediction Score: 0.8138999399179866
- Mean Citation Score: 598.1939679999998
- Max Citation Score: 691.5565
- Similarity Product: 538.7409691687525

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test